Mecka | $60,000,000 | (Jun 3, 2026)
Novellia | $18,000,000 | (Jun 3, 2026)
Plot | $10,000,000 | (Jun 3, 2026)
Contraline
United States
- Charlottesville, Virginia
- 03/06/2026
- Series B
- $92,500,000
Contraline is a venture-backed, clinical-stage biotechnology company at the forefront of male contraception.
- Industry Biotechnology Research
- Website https://www.contraline.com/
- LinkedIn https://www.linkedin.com/company/contraline/
Related People
Kevin EisenfratsCo Founder
United States -
Charlottesville, Virginia
Kevin co-founded Contraline and has been CEO since its inception. Contraline is a biotechnology company developing the world's first male contraceptives. Kevin has led Contraline from an idea to clinical-stage company, built a world-class team, and has brought in over $130M in funding.
Kevin's research interests also include cancer immunotherapy and non-hormonal female contraception. His degree is in Nanomedicine Engineering from the University of Virginia and he's an inventor on over 70 patents relating to novel drugs and medical devices. This work has landed Kevin on both Forbes 30 Under 30 in Healthcare as well as MIT Tech Review 35 Innovators Under 35.
Kevin is an active angel investor and startup advisor, with a focus on biotech, deep tech, and women's health companies.
KOSMOS | $5,000,000 | (Jun 3, 2026)
StratusGrid | $3,000,000 | (Jun 3, 2026)
Subtle Medical | $33,000,000 | (Jun 3, 2026)
Tavo Biotherapeutics | $17,000,000 | (Jun 3, 2026)
Gigaton | $26,000,000 | (Jun 3, 2026)
Inherent | $50,000,000 | (Jun 2, 2026)